4//SEC Filing
Sutherland Everett Rand 4
Accession 0001209191-21-056067
CIK 0001693415other
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 7:34 PM ET
Size
6.1 KB
Accession
0001209191-21-056067
Insider Transaction Report
Form 4
Sutherland Everett Rand
President
Transactions
- Sale
Stock Option (right to buy)
2021-09-14−300,000→ 0 totalExercise: $16.37Exp: 2031-03-22→ Common Stock (300,000 underlying)
Footnotes (2)
- [F1]As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
- [F2]This option was granted on March 22, 2021. This option will vest as to 25% of the shares on March 22, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 22, 2025.
Documents
Issuer
Translate Bio, Inc.
CIK 0001693415
Entity typeother
Related Parties
1- filerCIK 0001852880
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 7:34 PM ET
- Size
- 6.1 KB